4.7 Editorial Material

Minimal Residual Disease in Breast Cancer: In Blood Veritas

期刊

CLINICAL CANCER RESEARCH
卷 20, 期 10, 页码 2505-2507

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-14-0370

关键词

-

类别

资金

  1. European Community [259015]
  2. AIRC Special Program Molecular Clinical Oncology [9970]
  3. AIRC IG [12812]
  4. Fondazione Piemontese per la Ricerca sul Cancro-ONLUS 5 per mille Ministero della Salute
  5. Ministero dell'Istruzione, dell'Universita e della Ricerca (progetto PRIN)

向作者/读者索取更多资源

blood-based molecular test might direct recommendations for systemic therapies in patients with early-stage breast cancer undergoing surgery with curative intent. A new study suggests that droplet digital PCR (ddPCR) can be used to detect cancer-specific DNA alterations in plasma with sensitivity suitable for monitoring minimal residual disease. (C) 2014 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据